Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $130 to $123.
Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $130 to $123.